Kubota Pharmaceutical Holdings: Decision to rationalize management by transferring research, development, and management bases from USA to Japan.
Kubota Pharmaceutical Holdings: Announcements of individual stocks on the monthly exercise status of the 28th subscription rights (with exercise price adjustment clause).
Kubota Pharmaceutical Holdings: (Correction) Partial correction of 'Japan Retinal Pigmentary Dystrophy Association submits request to PMDA for early approval of 'Emiclustat hydrochloride' a candidate for Stargardt disease treatment'.
Kubota Pharmaceutical Holdings: The Japan Macular Degeneration Association submitted a request letter to PMDA, seeking early approval for the candidate drug for Stargardt's disease treatment, Emixustat hydrochloride.
Kubota Pharmaceutical Holdings: Notice regarding the monthly exercise status of the 28th Stock Acquisition Rights (with exercise price amendment clause)
KUBOTA PHARMACEUTICAL HLDGS: Notice of obtaining a new patent in the US
KUBOTA PHARMACEUTICAL HLDGS: [Delayed] Consolidated financial results for the 3 months ended March 31, 2024 (based on IFRS)
KUBOTA PHARMACEUTICAL HLDGS: Announcement of speakers at ARVO (Vision and Ophthalmology Research Association) 2024 Annual General Meeting
KUBOTA PHARMACEUTICAL HLDGS: Notice of obtaining a new patent in the US
KUBOTA PHARMACEUTICAL HLDGS: Notice about specific clinical research using the at-home/remote ophthalmology retinal monitoring device “eyeMO”
KUBOTA PHARMACEUTICAL HLDGS: Notice regarding the monthly exercise status of the 28th Stock Acquisition Rights (with exercise price amendment clause)
Kubota Pharmaceutical Holdings: Notice regarding the monthly exercise status of the 28th Stock Acquisition Rights (with exercise price amendment clause)
Kubota Pharmaceutical Holdings: Business Plan and Growth Potential Materials
Kubota Pharmaceutical Holdings: Partial Correction: Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 (under IFRS)
Kubota Pharmaceutical Holdings: Notice regarding the recording of impairment losses on fixed assets
Kubota Pharmaceutical Holdings: (Correction) Partial Corrections to the “Notice Concerning Reduction in the Amount of Capital (Capital Reduction) and Disposal of Other Capital Surplus Funds”
Kubota Pharmaceutical Holdings: Notice Concerning the Monthly Exercise Status of the 28th Stock Acquisition Rights (with Exercise Price Amendment Clause)
Kubota Pharmaceutical Holdings: Notice of acquisition of a new patent in the US
Kubota Pharmaceutical Holdings: Notice Concerning Decrease in the Amount of Capital (Capital Reduction) and Disposal of Other Capital Surplus Funds
Kubota Pharmaceutical Holdings: Notice of obtaining a new patent in the US
No Data